I. Garner

发表

HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer

A. Ashworth, D. Mukhopadhyay, Robert Brown, 2020, Cell reports.

Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma

I. McNeish, K. Blyth, P. Adams, 2022, Molecular cancer therapeutics.

Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance

Robert Brown, J. Gallon, J. Flanagan, 2021, Clinical epigenetics.

Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance

Robert Brown, J. Gallon, J. Flanagan, 2021, Clinical Epigenetics.

Is There a Role for Epigenetic Therapies in Modulating DNA Damage Repair Pathways to Enhance Chemotherapy and Overcome Drug Resistance?

Robert Brown, I. Garner, 2022, Cancers.

Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis

G. Laurent, A. Wells, D. Abraham, 2016, Clinical science.

Dual G9A and EZH2 inhibition stimulates an anti-tumour immune response in ovarian high-grade serous carcinoma

I. McNeish, K. Blyth, P. Adams, 2021, bioRxiv.

G-quadruplex structures regulate long-range transcriptional reprogramming to promote drug resistance in ovarian cancer

I. Garner, I. McNeish, Robert Brown, 2024, bioRxiv.